{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:10:56Z","timestamp":1769886656663,"version":"3.49.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100032550","name":"Zydus Lifesciences Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032550","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Zintrodiazine (ZY-19489) is a novel triaminopyrimidine-class antimalarial with potent activity against Plasmodium falciparum, including resistant strains. To support paediatric development and meet regulatory requirements, we conducted a comprehensive juvenile toxicity study of Zintrodiazine in rats, focusing on growth, neurodevelopment and toxicokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Wistar rats were administered vehicle and 30, 45 or 60\u2005mg\/kg\/day Zintrodiazine orally from postnatal day (PND) 10\u201345, followed by a 4-week recovery (PND 46\u201373). Endpoints included clinical observations, neurobehavioural assays (open field, acoustic startle\/pre-pulse inhibition and Morris water maze), sexual maturation, bone growth, clinical pathology, organ weights and histopathology. Toxicokinetic profiling at PND 21 and 45 assessed age- and sex-related exposure differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No treatment-related mortality, clinical signs or developmental impairment were observed. Body weight, food intake, sexual maturation and femur length were unaffected. Neurobehavioural performance remained normal across all assays. Transient, non-dose-dependent changes in liver and renal biomarkers observed at terminal phase resolved at the end of recovery. Minimal, reversible vacuolation consistent with phospholipidosis was observed in the liver, lymphoid, pulmonary and adrenal tissues at \u226530\u2005mg\/kg\/day, without inflammation or necrosis. Systemic exposure was dose-proportional; females exhibited higher parent compound and metabolite (ZY-20486) levels, while metabolite exposure declined with age, consistent with maturational biotransformation. The no-observed-adverse-effect level was 60\u2005mg\/kg\/day (Cmax \u22641572\u2005ng\/mL; AUClast \u226435\u200a592\u2005h\u00b7ng\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Zintrodiazine demonstrated a favourable juvenile safety profile, with no adverse effects on growth, neurodevelopment or sexual maturation at clinically relevant exposures. These findings provide critical regulatory data supporting progression into paediatric clinical trials and highlight Zintrodiazine\u2019s potential as a safe and effective antimalarial for children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag008","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:39:36Z","timestamp":1767875976000},"source":"Crossref","is-referenced-by-count":0,"title":["Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8714-4647","authenticated-orcid":false,"given":"Hitesh A","family":"Kadu","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viral I","family":"Rajwadi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar V","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul B","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik P","family":"Panchal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-7408","authenticated-orcid":false,"given":"Laxit K","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3703-5703","authenticated-orcid":false,"given":"Jitendra H","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7018-384X","authenticated-orcid":false,"given":"Ramchandra K","family":"Ranvir","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harilal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism and Pharmacokinetics, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi R","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism and Pharmacokinetics, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9322-9865","authenticated-orcid":false,"given":"Beata","family":"Kusmider","sequence":"additional","affiliation":[{"name":"Non-Clinical Pharmacology & Toxicology, MMV Medicines for Malaria Venture , Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Tornesi","sequence":"additional","affiliation":[{"name":"Non-Clinical Pharmacology & Toxicology, MMV Medicines for Malaria Venture , Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-2513","authenticated-orcid":false,"given":"Abraham","family":"Nyska","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7765-3193","authenticated-orcid":false,"given":"Rajesh","family":"Sundar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-1435","authenticated-orcid":false,"given":"Mukul R","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited , Ahmedabad ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026013100165402700_dkag008-B1","author":"World Health Organization"},{"key":"2026013100165402700_dkag008-B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12936-022-04303-6","article-title":"The economic burden of malaria: a systematic review","volume":"21","author":"Andrade","year":"2022","journal-title":"Malar J"},{"key":"2026013100165402700_dkag008-B3","doi-asserted-by":"publisher","first-page":"e86737","DOI":"10.1371\/journal.pone.0086737","article-title":"Clinical features and outcome in children with severe Plasmodium falciparum malaria: a meta-analysis","volume":"9","author":"Manning","year":"2014","journal-title":"PLoS One"},{"key":"2026013100165402700_dkag008-B4","first-page":"1","volume-title":"Encyclopedia of Malaria","author":"Yau","year":"2014"},{"key":"2026013100165402700_dkag008-B5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12639-024-01758-z","article-title":"A comprehensive review of cerebral malaria","volume":"49","author":"Beniwal","year":"2025","journal-title":"J Parasit Dis"},{"key":"2026013100165402700_dkag008-B6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/infdis\/jiw338","article-title":"Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria","volume":"214","author":"Tchaparian","year":"2016","journal-title":"J Infect Dis"},{"key":"2026013100165402700_dkag008-B7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/bcp.16132","article-title":"Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants","volume":"91","author":"Banda","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026013100165402700_dkag008-B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12936-015-0682-7","article-title":"Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem\u00ae)","volume":"14","author":"Tiono","year":"2015","journal-title":"Malar J"},{"key":"2026013100165402700_dkag008-B9","author":"The International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) 2020"},{"key":"2026013100165402700_dkag008-B10","author":"European Medicines Agency (EMA)"},{"key":"2026013100165402700_dkag008-B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-4939-7172-5_2","article-title":"Juvenile nonclinical safety studies in support of pediatric drug development","volume":"1641","author":"Barrow","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2026013100165402700_dkag008-B12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S1473-3099(16)30020-2","article-title":"Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial","volume":"16","author":"Sirima","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026013100165402700_dkag008-B13","author":"Global Partnership to Roll Back Malaria"},{"key":"2026013100165402700_dkag008-B14","first-page":"731","article-title":"Management of malaria in children: update 2008","volume":"45","author":"Infectious Diseases Chapter, Indian Academy of Pediatrics","year":"2008","journal-title":"Indian Pediatr"},{"key":"2026013100165402700_dkag008-B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(09)70320-2","article-title":"Pharmacogenetics of antimalarial drugs: effect on metabolism and transport","volume":"9","author":"Kerb","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2026013100165402700_dkag008-B16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1473-3099(21)00679-4","article-title":"Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study","volume":"22","author":"Barber","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026013100165402700_dkag008-B17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1021\/acsinfecdis.3c00588","article-title":"A pH fingerprint assay to identify inhibitors of multiple validated and potential antimalarial drug targets","volume":"10","author":"Lindblom","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026013100165402700_dkag008-B18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(22)00294-8","article-title":"Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study","volume":"22","author":"Radohery","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026013100165402700_dkag008-B19","author":"Zydus Lifesciences Limited"},{"key":"2026013100165402700_dkag008-B20","author":"Buelke-Sam"},{"key":"2026013100165402700_dkag008-B21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/1091581817699975","article-title":"Points to consider in designing and conducting juvenile toxicology studies","volume":"36","author":"Kim","year":"2017","journal-title":"Int J Toxicol"},{"key":"2026013100165402700_dkag008-B22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/10915818221145327","article-title":"Juvenile bone toxicity: study considerations, regulations, and techniques for assessment","volume":"42","author":"Morford","year":"2023","journal-title":"Int J Toxicol"},{"key":"2026013100165402700_dkag008-B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/neurosci6020027","article-title":"Methods for assessing neurodevelopmental disorders in mice: a critical review of behavioral tests and methodological considerations searching to improve reliability","volume":"6","author":"Echefu","year":"2025","journal-title":"NeuroSci"},{"key":"2026013100165402700_dkag008-B24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-319-11578-8_17","volume-title":"Rodent Model as Tools in Ethical Biomedical Research","author":"Quillfeldt","year":"2016"},{"key":"2026013100165402700_dkag008-B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0165-0270(84)90007-4","article-title":"Developments of a water-maze procedure for studying spatial learning in the rat","volume":"11","author":"Morris","year":"1984","journal-title":"J Neurosci Methods"},{"key":"2026013100165402700_dkag008-B26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/toxsci\/66.2.313","article-title":"Analysis of rodent growth data in toxicology studies","volume":"66","author":"Hoffman","year":"2002","journal-title":"Toxicol Sci"},{"key":"2026013100165402700_dkag008-B27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1210\/en.2015-1937","article-title":"Delayed neuroendocrine sexual maturation in female rats after a very low dose of bisphenol A through altered GABAergic neurotransmission and opposing effects of a high dose","volume":"157","author":"Franssen","year":"2016","journal-title":"Endocrinology"},{"key":"2026013100165402700_dkag008-B28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/10408440091159194","article-title":"Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee","volume":"30","author":"Stoker","year":"2000","journal-title":"Crit Rev Toxicol"},{"key":"2026013100165402700_dkag008-B29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00002018-199512060-00003","article-title":"CNS adverse events associated with antimalarial agents. Fact or fiction?","volume":"12","author":"Phillips-Howard","year":"1995","journal-title":"Drug Saf"},{"key":"2026013100165402700_dkag008-B30","first-page":"1","volume-title":"Specifications for the Conduct of Toxicity Studies by the Division of Translational Toxicology at the National Institute of Environmental Health Sciences","author":"Behl","year":"2023"},{"key":"2026013100165402700_dkag008-B31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/toxics11050431","article-title":"Neurobehavioral responses and toxic brain reactions of juvenile rats exposed to iprodione and chlorpyrifos, alone and in a mixture","volume":"11","author":"Abd-Elhakim","year":"2023","journal-title":"Toxics"},{"key":"2026013100165402700_dkag008-B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2131\/fts.7.85","article-title":"Utility of measuring long bone length in toxicity studies: results of a 14-day repeated dose oral toxicity study of dexamethasone in young, periadolescent and adult rats","volume":"7","author":"Noguchi","year":"2020","journal-title":"Fundam Toxicol Sci"},{"key":"2026013100165402700_dkag008-B33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/bdr2.2071","article-title":"Assessment of postnatal femur development in Wistar Han rats","volume":"114","author":"Campion","year":"2022","journal-title":"Birth Defects Res"},{"key":"2026013100165402700_dkag008-B34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1177\/01926233211041338","article-title":"Brief synopsis: \u201cinstruction manual for juvenile clinical pathology\u201d","volume":"49","author":"Provencher","year":"2021","journal-title":"Toxicol Pathol"},{"key":"2026013100165402700_dkag008-B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42826-024-00194-7","article-title":"Age-related changes in hematological and biochemical profiles of Wistar rats","volume":"40","author":"Patel","year":"2024","journal-title":"Lab Anim Res"},{"key":"2026013100165402700_dkag008-B36","doi-asserted-by":"publisher","first-page":"5059761","DOI":"10.1155\/2022\/5059761","article-title":"Seventy-day toxicity study in juvenile Sprague-Dawley rats with semicarbazide (SEM) from weaning to sexual maturity","volume":"2022","author":"Malashetty","year":"2022","journal-title":"J Toxicol"},{"key":"2026013100165402700_dkag008-B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1293\/tox.21.9","article-title":"Drug-induced phospholipidosis: pathological aspects and its prediction","volume":"21","author":"Nonoyama","year":"2008","journal-title":"J Toxicol Pathol"},{"key":"2026013100165402700_dkag008-B38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/01926230490431754","article-title":"Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864","volume":"32","author":"Rudmann","year":"2004","journal-title":"Toxicol Pathol"},{"key":"2026013100165402700_dkag008-B39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.2008.058248","article-title":"Histological patterns in drug-induced liver disease","volume":"62","author":"Ramachandran","year":"2009","journal-title":"J Clin Pathol"},{"key":"2026013100165402700_dkag008-B40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-3-031-12398-6_20","volume-title":"Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology","author":"Ofori","year":"2022"},{"key":"2026013100165402700_dkag008-B41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/toxsci\/kfae056","article-title":"The association between histopathologic effects and liver weight changes induced in mice and rats by chemical exposures: an analysis of the data from Toxicity Reference Database (ToxRefDB)","volume":"200","author":"Mezencev","year":"2024","journal-title":"Toxicol Sci"},{"key":"2026013100165402700_dkag008-B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden","year":"2019","journal-title":"Biol Chem"},{"key":"2026013100165402700_dkag008-B43","author":"Maronpot"},{"key":"2026013100165402700_dkag008-B44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0192623316672352","article-title":"Is it adverse, nonadverse, adaptive, or artifact?","volume":"45","author":"Pandiri","year":"2017","journal-title":"Toxicol Pathol"},{"key":"2026013100165402700_dkag008-B45","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1177\/0192623309352496","article-title":"A strategy for risk management of drug-induced phospholipidosis","volume":"37","author":"Chatman","year":"2009","journal-title":"Toxicol Pathol"},{"key":"2026013100165402700_dkag008-B46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1039\/9781788016414-00382","volume-title":"The Medicinal Chemist\u2019s Guide to Solving ADMET Challenges","author":"Goracci","year":"2021"},{"key":"2026013100165402700_dkag008-B47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1248\/jhs.55.325","article-title":"Sex differences of drug-metabolizing enzyme: female predominant expression of human and mouse cytochrome P450 3A isoforms","volume":"55","author":"Sakuma","year":"2009","journal-title":"J Health Sci"},{"key":"2026013100165402700_dkag008-B48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1292\/jvms.09-0397","article-title":"Changes in the gene expression and enzyme activity of hepatic cytochrome P450 in juvenile Sprague-Dawley rats","volume":"72","author":"Asaoka","year":"2010","journal-title":"J Vet Med Sci"},{"key":"2026013100165402700_dkag008-B49","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/1471-2164-11-675","article-title":"Age and sex dependent changes in liver gene expression during the life cycle of the rat","volume":"11","author":"Kwekel","year":"2010","journal-title":"BMC Genomics"},{"key":"2026013100165402700_dkag008-B50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13293-017-0127-9","article-title":"Sex and age differences in the expression of liver microRNAs during the life span of F344 rats","volume":"8","author":"Kwekel","year":"2017","journal-title":"Biol Sex Differ"},{"key":"2026013100165402700_dkag008-B51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fphar.2016.00437","article-title":"Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children","volume":"7","author":"Neumann","year":"2016","journal-title":"Front Pharmacol"},{"key":"2026013100165402700_dkag008-B52","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/jcph.1493","article-title":"Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Bad\u00e9e","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2026013100165402700_dkag008-B53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1124\/dmd.119.086363","article-title":"Developmental expression of the cytosolic sulfotransferases in human liver","volume":"47","author":"Dubaisi","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2026013100165402700_dkag008-B54","author":"European Medicines Agency (EMA)"},{"key":"2026013100165402700_dkag008-B55","author":"U.S. Food and Drug Administration"},{"key":"2026013100165402700_dkag008-B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cts.12843","article-title":"Pediatric pharmacokinetics and dose predictions: a report of a satellite meeting to the 10th juvenile toxicity symposium","volume":"14","author":"van Groen","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2026013100165402700_dkag008-B57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40268-020-00295-3","article-title":"Prediction of clearance in children from adults following drug-drug interaction studies: application of age-dependent exponent model","volume":"20","author":"Mahmood","year":"2020","journal-title":"Drugs R D"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag008\/66610369\/dkag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag008\/66610369\/dkag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:17:07Z","timestamp":1769836627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag008\/8443072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag008","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkag008"}}